Nuvectis Pharma, Inc. (NVCT) – What Are Analysts Thinking About This Stock?

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $36.25.

A number of analysts recently weighed in on NVCT shares. Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a report on Tuesday, September 1st. Weiss Ratings upgraded Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research note on Tuesday, September 1st. Cantor Fitzgerald assumed coverage on shares of Nuvectis Pharma in a research report on Monday, August 24th. They set an “overweight” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $39.00 price objective on shares of Nuvectis Pharma in a research report on Thursday, September 24th.

Nuvectis Pharma Stock Performance

NASDAQ NVCT opened at $18.36 on Friday. Nuvectis Pharma has a fifty-two week low of $5.55 and a fifty-two week high of $29.27. The stock has a market cap of $599.34 million, a PE ratio of -14.02 and a beta of -0.24. The firm’s fifty day moving average price is $21.64 and its two-hundred day moving average price is $14.51.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). As a group, sell-side analysts predict that Nuvectis Pharma will post -1.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc purchased a new position in shares of Nuvectis Pharma during the 2nd quarter valued at $31,000. Bank of America Corp DE purchased a new stake in Nuvectis Pharma during the second quarter valued at about $218,000. Avalon Trust Co purchased a new position in shares of Nuvectis Pharma during the 2nd quarter valued at about $257,000. Deutsche Bank AG purchased a new position in shares of Nuvectis Pharma during the second quarter worth approximately $310,000. Finally, Bank of New York Mellon Corp purchased a new position in Nuvectis Pharma in the 2nd quarter worth $676,000. 96.77% of the stock is owned by hedge funds and other institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.